Why the study?
Does prior pharmacogenetic testing for CYP2C19 improve cost-utility in patients with acute coronary syndrome after stent implanting?
Does prior pharmacogenetic testing for CYP2C19 improve cost-utility in patients with acute coronary syndrome after stent implanting?
Pharmacogenetic testing for CYP2C19 to guide the use of prasugrel in slow and intermediate metabolizers is a cost-effective strategy for dual antiplatelet therapy in patients with acute coronary syndrome post-stenting.
The article contains the results of a comparison pharmacoeconomical cost-utility analysis of several options for dual antiplatelet therapy in patients with acute coronary syndrome after stent implanting. The costs for treatment alternatives with and without prior pharmacogenetic testing for CYP2C19 were calculated. According to the results of the analysis the most cost-effective treatment option for patients with acute coronary syndrome is prior pharmacogenetic testing and the choice of the antiplatelet drug prasugrel in slow and intermediate metabolizers (CUA: 289,111.00 rubles per QALY).
No takes yet. Share an insight, caveat, or question.
Абдуллаев et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: